ArticleLa Radiologia medica2026
Microwave ablation for residual ground-glass nodule-like lung cancer after video-assisted thoracoscopic surgery: a retrospective, large-sample, multicenter study.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe management of residual or new ground-glass nodule (GGN)-like lung cancer after video-assisted thoracoscopic surgery (VATS) is challenging for patients who are not suitable for reoperation. This retrospective, large-sample, multicenter study aimed to evaluate the feasibility, safety, and preliminary efficacy of microwave ablation (MWA) for residual GGN-like lung cancer after VATS in early-stage lung cancer.
methodsA total of 216 patients with 216 residual GGN-like lung cancers who underwent 235 procedures of CT-guided percutaneous MWA after VATS (R0) of stage I-IIA lung adenocarcinoma from July 2016 to December 2023 were included in the study. The primary endpoints were technical success, complications, and pulmonary function test (PFT) variations after the MWA procedure. The secondary endpoints were local progression-free survival (LPFS) and overall survival (OS).
resultsThe rate of technical success was 100%. The major complications after MWA included pneumothorax (12.3%, 29/235), pleural effusion (5.5%, 13/235), pulmonary infection (2.6%, 6/235), hydropneumothorax (1.3%, 3/235), intrathoracic hemorrhage (0.4%, 1/235), and bronchopleural fistula (0.4%, 1/235). No MWA procedure-related death was observed. The PFT at 1-3 months after MWA was not significantly different from the baseline. The median follow-up duration was 58.5 months, and the 1-, 3- and 5-year OS rates were 100%, 99.1% and 96.3%, respectively. The median follow-up period after MWA was 33.8 months, and the 1-, 2- and 3-year LPFS rates were 100%, 97.7% and 96.3%, respectively.
conclusionsCT-guided percutaneous MWA is a safe, effective, and potentially curative approach for patients with residual GGN-like lung cancer after VATS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.